It has been found in a phase I study that patients taking Eli Lilly's investigational obesity drug eloralintide lost more ...

The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India ...

Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

PARIS, June 21, 2025 (BSS/AFP) - A new generation of weight-loss drugs has proven remarkably effective, hugely popular and ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

The shipments have propelled Ireland, a country of only 5.4 million people, to the second-largest goods-trade imbalance with ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for ...